USANA Health Sciences Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Jim Brown
Chief executive officer
US$2.5m
Total compensation
| CEO salary percentage | 28.7% |
| CEO tenure | 8.2yrs |
| CEO ownership | n/a |
| Management average tenure | 7.9yrs |
| Board average tenure | 6.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 28 2024 | n/a | n/a | US$54m |
| Jun 29 2024 | n/a | n/a | US$55m |
| Mar 30 2024 | n/a | n/a | US$62m |
| Dec 30 2023 | US$2m | US$710k | US$64m |
| Sep 30 2023 | n/a | n/a | US$60m |
| Jul 01 2023 | n/a | n/a | US$63m |
| Apr 01 2023 | n/a | n/a | US$65m |
| Dec 31 2022 | US$2m | US$624k | US$69m |
| Oct 01 2022 | n/a | n/a | US$77m |
| Jul 02 2022 | n/a | n/a | US$89m |
| Apr 02 2022 | n/a | n/a | US$108m |
| Jan 01 2022 | US$2m | US$600k | US$117m |
| Oct 02 2021 | n/a | n/a | US$136m |
| Jul 03 2021 | n/a | n/a | US$139m |
| Apr 03 2021 | n/a | n/a | US$129m |
| Jan 02 2021 | US$2m | US$599k | US$125m |
| Sep 26 2020 | n/a | n/a | US$116m |
| Jun 27 2020 | n/a | n/a | US$110m |
| Mar 28 2020 | n/a | n/a | US$103m |
| Dec 28 2019 | US$2m | US$559k | US$101m |
| Sep 28 2019 | n/a | n/a | US$102m |
| Jun 29 2019 | n/a | n/a | US$109m |
| Mar 30 2019 | n/a | n/a | US$121m |
| Dec 29 2018 | US$2m | US$534k | US$126m |
Compensation vs Market: Jim's total compensation ($USD2.47M) is above average for companies of similar size in the German market ($USD1.45M).
Compensation vs Earnings: Jim's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Jim Brown (55 yo)
8.2yrs
Tenure
US$2,472,017
Compensation
Mr. Jim Brown has been the President of USANA Health Sciences Inc. since November 2016 and served as its Chief Operating Officer since November 2013 until October 2019. He serves as Chief Executive Officer...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 7.7yrs | US$3.91m | 0.064% € 427.4k | |
| CEO & President | 8.2yrs | US$2.47m | no data | |
| Chief Financial Officer | 7.7yrs | US$1.47m | no data | |
| Chief Operating Officer | 5.3yrs | US$1.42m | no data | |
| Chief Legal Officer | 6.5yrs | US$1.29m | no data | |
| Chief Communications & Marketing Officer | 13.1yrs | US$1.15m | no data | |
| Founder & Chairman Emeritus | 33yrs | no data | 40.62% € 271.7m | |
| Executive Director of Product Development & Technology | 12.1yrs | no data | no data | |
| Chief Scientific Officer | 8.4yrs | no data | no data | |
| Chief Information Officer | no data | no data | no data | |
| Executive Director of Investor Relations & Business Development | no data | no data | no data | |
| Chief People Officer | 3.9yrs | US$637.78k | 0% € 0 |
7.9yrs
Average Tenure
58yo
Average Age
Experienced Management: USJ's management team is seasoned and experienced (7.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 7.7yrs | US$3.91m | 0.064% € 427.4k | |
| Founder & Chairman Emeritus | 4.7yrs | no data | 40.62% € 271.7m | |
| Lead Independent Director | 16.3yrs | US$251.60k | no data | |
| Independent Director | 6.1yrs | US$231.40k | 0.021% € 137.7k | |
| Independent Director | 5.3yrs | US$218.40k | 0.034% € 225.8k | |
| Member of Scientific Advisory Council | no data | no data | no data | |
| Member of Scientific Advisory Council | no data | no data | no data | |
| Chairperson of Scientific Advisory Council | 21yrs | no data | no data | |
| Member of Scientific Advisory Council | no data | no data | no data | |
| Member of Scientific Advisory Council | no data | no data | no data | |
| Independent Director | 8.7yrs | US$233.60k | 0.024% € 158.7k | |
| Independent Director | 2.5yrs | US$218.40k | 0.022% € 148.6k |
6.9yrs
Average Tenure
68yo
Average Age
Experienced Board: USJ's board of directors are considered experienced (6.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 10:47 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/28 |
| Annual Earnings | 2023/12/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
USANA Health Sciences, Inc. is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Amy Vinson | Avondale Partners |
| Scott Van Winkle | Canaccord Genuity |
| Song Xue | D.A. Davidson & Co. |